NovoCure Limited
Price Action
Technical Summary
STAGE 2 UPTRENDNovoCure Limited is in a confirmed Stage 2 uptrend, with price holding above all major moving averages and trend structure remaining intact. Relative strength is moderate (RS Rating: 77), indicating performance broadly in line with the market. Earnings contraction of 100% provides fundamental context to the price action. Investors should exercise caution due to high volatility (77% annualized), which requires wider risk management.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $16.25 | +9.03% | ABOVE |
| 50 SMA | $16.43 | +7.87% | ABOVE |
| 100 SMA | $14.20 | +24.79% | ABOVE |
| 150 SMA | $13.74 | +28.98% | ABOVE |
| 200 SMA | $13.53 | +30.98% | ABOVE |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is NVCR in an uptrend right now?
NVCR has a trend score of 4/4 based on Minervini's Stage Analysis. Yes, NVCR is in a Stage 2 uptrend with price above all major moving averages (50, 100, 150, 200 SMA) properly stacked.
Is NVCR overbought or oversold?
NVCR's RSI (14) is 58. The stock is in neutral territory, neither overbought nor oversold.
Is NVCR outperforming the market?
NVCR has a Relative Strength (RS) Rating of 77 out of 99. NVCR is performing about average compared to the market.
Where is NVCR in its 52-week range?
NVCR is trading at $17.72, which is 94% of its 52-week high ($18.92) and 87% above its 52-week low ($9.82).
How volatile is NVCR?
NVCR has a Beta of 1.88 and 52-week volatility of 77%. It's more volatile than the S&P 500 - expect bigger swings.